Drug intelligence / Profile preview

BG-2104

Development stage: Preclinical
Lead developer: Guangzhou Bio-gene Technology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies

Overview

BG-2104 is a chimeric antigen receptor T cell (CAR-T) therapy under development by Guangzhou Bio-gene Technology. It is being investigated for the treatment of neoplasms, specifically solid tumors. As a CAR-T therapy, it involves genetically engineering T cells to express a receptor that targets specific antigens on tumor cells, enabling targeted immune-mediated destruction of cancerous tissue. The drug is currently in preclinical development and has not yet entered clinical trials[1].

Beyond the preview

Go deeper on BG-2104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BG-2104.

Explore the full profile